secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENZ Therapeutics, Inc. (LENZ)
CIK:        0001815776
Form:       8-K
Filed at:   2023-01-05T23:59:59+00:00
Accession:  0000950170-23-000228
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Graphite Bio pauses Phase 1/2 sickle cell gene therapy study after serious adverse event in first patient
--------------------------------------------------------------------------------

- First patient dosed with nula-cel experienced prolonged pancytopenia requiring ongoing transfusion and growth factor support.
- Company will not meet guidance for initial proof-of-concept data in mid-2023; IND for GPH102 in beta-thalassemia delayed beyond mid-2024.
- Company working to identify operational efficiencies to extend cash runway to at least 2026; will provide business update by end of Q1 2023.
- Patient achieved neutrophil engraftment with no evidence of myelodysplasia; event reported to FDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815776/000095017023000228/0000950170-23-000228-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815776/000095017023000228/grph-20230105.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-000228

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer